Remedium Capital Partners, LLC
Long book
$281.2M
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
+56.0%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsRemedium Capital Partners, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $281.2M US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: ORUKA THERAPEUTICS INC, SPYRE THERAPEUTICS INC, DAMORA THERAPEUTICS INC, APOGEE THERAPEUTICS INC, JADE BIOSCIENCES INC.
We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
+35.5%
Q1 2026
+56.0%
Sector allocation
Healthcare 100%
Long book by quarter
What does Remedium Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.6M | $76.8M | 27.3% | +0.9% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.5M | $73.5M | 26.1% | Held |
| DMRA DAMORA THERAPEUTICS INC | Healthcare | 2.0M | $53.0M | 18.8% | +1597.9% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 583.6K | $49.1M | 17.5% | Held |
| JBIO JADE BIOSCIENCES INC | Healthcare | 1.6M | $22.2M | 7.9% | Held |
| CBIO CRESCENT BIOPHARMA INC. | Healthcare | 361.3K | $6.6M | 2.4% | Held |